Skip to content

Abstract B043: Targeting dual CDK9 and KRASG12D selective inhibition as a novel combination therapy in pancreatic ductal adenocarcinoma

Sep 2026 · Cancer Research · 0 citations

TL;DR

A patient-derived cancer organoid (PCO) model that is MYC-amplified is examined to assess the activity of combining CDK9 inhibition (SLS009) with tricomplex RAS (ON inhibitors) studying both RMC-6236 and RMC-9805 and significantly augments the induction of apoptosis and necrosis compared to single agent activity.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer related mortality with a critical need for novel therapeutic strategies. Cyclin dependent kinase 9 (CDK9) is a transcriptional regulator of RNA polymerase II (Pol II) by phosphorylation of serine residues on the C terminal domain of the positive transcription elongation factor (pTEF). Tri-complex RAS(ON) inhibitors are emerging in clinical practice including daraxonrasib (RMC-6236) and zoldonrasib (RMC-9805), a KRASG12D selective inhibitor with favorable toxicity. Here, we examine a patient-derived cancer organoid (PCO) model that is MYC-amplified to assess the activity of combining CDK9 inhibition (SLS009) with tricomplex RAS (ON inhibitors) studying both RMC-6236 and RMC-9805. PCOs were assayed using medium throughput 96 well assay (Ibidi, Inc) for high content imaging (Cytation 5). Single and dual agent activity of SLS009 (200nM) and RMC-6236 (100nM) was assessed with an assay endpoint of 72 hours. RMC-6236 was treated continuously, while SLS009 was removed after 24 hours to mimic in vivo pharmacokinetics. Initial response was assessed by normalized change in PCO area after 72 hours. Subsequent viability staining was performed for apoptosis (Caspase-3/7) and necrosis (TOPRO3). Statistical analysis was conducted using one-way ANOVA followed by Tukey’s post hoc test to compare the mean percentage of area stained between treatment groups. SLS009 was assessed for single agent activity to compared sensitivity across resistance to RMC-9805. Western blot analysis was performed for critical resistance mechanisms including c-MYC and MCL-1 using a LICOR M Odyssey system. SLS009 in combination with RMC-6236 significantly augments the induction of apoptosis and necrosis compared to single agent activity. Apoptosis staining as assessed for % area positive for the combination group increased to 36.49% relative to the negative control (6.965%, p<0.001), and in comparison to single agent SLS009 (17.88%, p<0.001) and RMC-6236 (2.781%, p=0.0086). Necrosis staining as assessed by % area positive for the combination group increased to 30.62% relative to the negative control (6.723%, p<0.001), in comparison to single agent SLS009 (14.51%, p<0.001) and RMC-6236 (2.702%, p=0.0044). Western blots of protein collected from naïve PCO and RMC-9805 resistant PCO treated with SLS009 for 24 hours showed potent decrease in c-MYC and MCL-1 activity. SLS009 was found to have improved potency as single agent IC50 (65.06 +/- 14.47nM SEM) in the RMC-9805 resistant PCO as compared to the naïve line (96.78 +/- 14.70nM SEM). The combination of transcriptional targeting with SLS009 in combination with tricomplex RAS (ON) inhibition significantly augments the induction of apoptosis and necrosis. Ongoing work includes evaluating biomarkers predictive of this response and activity across heterotopic in vivo models. Michela Cadarso, Paulina Esguerra, Lauryn Flannagan, Md Shahadat Hossan, Jeremy D. Kratz. Targeting dual CDK9 and KRASG12D selective inhibition as a novel combination therapy in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B043.

View source

Similar papers

Sep 2026

Abstract B127: Synthetic Lethality Through Combined BET and CDK9 Inhibition in MYC-Amplified Pancreatic Ductal Adenocarcinoma

It is demonstrated that dual BET and CDK9 inhibition promotes transcriptional pausing and suppresses key regulators in transcriptionally driven cancers, as well as demonstrating on-target transcriptional inhibition.

Paulina N. Esguerra, Michela Cadarso, Sasha Livingwell et al. · 0 citations
Aug 2026

MLN4924 suppresses pancreatic cancer progression and enhances chemosensitivity to gemcitabine by targeting the PTGS2/EGFR-PI3K/Akt/mTOR signaling axis.

Results demonstrate that MLN4924 exerts antitumor effects in pancreatic cancer by targeting the PTGS2-EGFR-PI3K/AKT/mTOR axis, providing a mechanistic rationale for its clinical application in pancreatic cancer therapy.

Min Wang, Y. Mou, Jiajie Qiu et al. · 0 citations
#gene editing Sep 2026

Abstract B067: Dissection of the in vitro response landscape in PDAC under KRAS inhibition reveals co-occurring conserved and adaptive transcription programs

In vitro perturbation is used to decipher the early transcriptional response programs in patient-derived 2D and 3D cell models of PDAC to KRAS inhibition and identify a robust RNA-based signature with potential utility for pharmacodynamic monitoring and the study of adaptive resistance.

H. Schürmann, J. Asche, S. Liffers et al. · 0 citations
Sep 2026

Abstract B094: CDK12 inhibition activates cGAS-STING-mediated antitumor immunity and enhances immune checkpoint blockade in basal-like PDAC

Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy with limited effective therapies. Using a patient-derived organoid-based drug screen, we identified cyclin-dependent kinase 12 (CDK12) as a promising therapeutic target, particularly in basal-like PDAC. CDK12 is a transcription-associated cycl...

Dosuke Iwadate, Keisuke Yamamoto, Hiroyuki Kato et al. · 0 citations
Sep 2026

Abstract A056: Targeting the mutant p53 cancer cell secretome sensitizes tumors to gemcitabine/nab-paclitaxel chemotherapy and reduces metastasis in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal and metastatic malignancy, with standard-of-care treatments, such as gemcitabine/nab-paclitaxel (GnP) offering limited improvement for patients with advanced disease. We and others have shown that co-targeting key factors in combination with chemotherapy...

Shona Ritchie, Victoria M. Tyma, Shanna Hafiz et al. · 0 citations
#protein folding Sep 2026

Abstract B052: Understanding latent resistance mechanisms and their phenotypes in pancreatic cancer organoids under KRASG12D inhibition

The rate of acquired resistance to Zoldonrasib was found to be rapid in PCO models and independent of EGF stimulation, and opposing signaling pathway activation in resistant PCOs to Zoldonrasib at 200nM dependent upon EGF stimulation was suggested.

Lauryn E. Flannagan, Michela Cadarso, Audrey G. Sawyer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.